Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis

References

• AlbaMAJennetteJCFalkRJPathogenesis of ANCA-associated pulmonary vasculitisSemin Respir Crit Care Med201839441342430404109
   PubMed Web of Science ®Google Scholar
• LaurinoSChaudhryABoothAConteGJayneDProspective study of TNF blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvementNephrol Dial Transplant201025103307331420368305
   PubMed Web of Science ®Google Scholar
• YatesMWattsRABajemaIMEULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitisAnn Rheum Dis20167591583159427338776
   PubMed Web of Science ®Google Scholar
• ShahSHruskovaZSegelmarkMTreatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximabAm J Nephrol2015414–529630126044574
   PubMed Web of Science ®Google Scholar
• ShanehbandiDMajidiJKazemiTBaradaranBAghebati-MalekiLCloning and molecular characterization of the cDNAs encoding the variable regions of an anti-CD20 monoclonal antibodyHum Antibodies20172611628269762
   PubMedGoogle Scholar
• SelmiCGeneraliEMassarottiMBianchiGSciréCANew treatments for inflammatory rheumatic diseaseImmunol Res2014602–327728825381481
   PubMed Web of Science ®Google Scholar
• Ito-IharaTOnoTNogakiFClinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritisNephron Clin Pract20061021c35c4216174989
   PubMedGoogle Scholar
• JayneDRChapelHAduDIntravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activityQJM200093743343910874052
   PubMed Web of Science ®Google Scholar
• GopaluniSJayneDClinical trials in vasculitisCurr Treatm Opt Rheumatol20162216117728936387
   PubMedGoogle Scholar
• NagelkerkeSQKuijpersTWImmunomodulation by IVIg and the role of Fc-Gamma receptors: classic mechanisms of action after all?Front Immunol20145823267425653650
   PubMed Web of Science ®Google Scholar
• FloreyOHaskardDOSphingosine 1-phosphate enhances Fc gamma receptor-mediated neutrophil activation and recruitment under flow conditionsJ Immunol200918342330233619620297
   PubMed Web of Science ®Google Scholar
• van TimmerenMMvan der VeenBSStegemanCAIgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritisJ Am Soc Nephrol20102171103111420448018
   PubMed Web of Science ®Google Scholar
• KameokaYKouraMMatsudaJEstablishment of a library having 204 effective clones of recombinant single chain fragment of variable region (hScFv) of IgG for vasculitis treatmentADC Lett Infect Dis Control2017424447
   Google Scholar
• KinjohKKyogokuMGoodRAGenetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitisProc Natl Acad Sci U S A1993908341334178475090
   PubMed Web of Science ®Google Scholar
• FeiglFAngerVEine Tüpfelreaktion Zum Nachweis von nativem Eiweiß [A spotting reaction to detect native proteins]Microchim Acta19372107110 German
   Google Scholar
• HurstJLBeynonRJArmstrongSDMolecular heterogeneity in major urinary proteins of Mus musculus subspecies: potential candidates involved in speciationSci Rep2017714499228337988
   PubMed Web of Science ®Google Scholar
• SuzukiKNagaoTItabashiMA novel autoantibody against moesin in the serum of patients with MPO-ANCA-associated vasculitisNephrol Dial Transplant20142961168117724319012
   PubMed Web of Science ®Google Scholar
• BajemaIMBruijnJACasianAThe European Vasculitis Society 2016 Meeting reportKidney Int Rep2017261018103129634043
   PubMed Web of Science ®Google Scholar
• MohanNEdwardsETCuppsTRLeukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agentsJ Rheumatol200431101955195815468359
   PubMed Web of Science ®Google Scholar
• StoneJHMerkelPASpieraRRituximab versus cyclophosphamide for ANCA-associated vasculitisN Engl J Med2010363322123220647199
   PubMed Web of Science ®Google Scholar
• JonesRBFurutaSTervaertJWRituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trialAnn Rheum Dis20157461178118225739829
   PubMed Web of Science ®Google Scholar
• ShepardHMPhillipsGLD ThanosCFeldmannMDevelopments in therapy with monoclonal antibodies and related proteinsClin Med2017173220232
   PubMed Web of Science ®Google Scholar
• BonnardTTennantZNiegoBNovel thrombolytic drug based on thrombin cleavable microplasminogen coupled to a single-chain antibody specific for activated GPIIb/IIIaJ Am Heart Assoc201762e00453528159824
   PubMed Web of Science ®Google Scholar
• JinHLiCLiDConstruction and characterization of a CTLA-4-targeted scFv-melittin fusion protein as a potential immunosuppressive agent for organ transplantCell Biochem Biophys20136731067107423608813
   PubMed Web of Science ®Google Scholar
• ScallonBJMooreMATrinhHKnightDMGhrayebJChimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functionsCytokine1995732512597640345
   PubMed Web of Science ®Google Scholar
• DavisTACzerwinskiDKLevyRTherapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expressionClin Cancer Res19995361161510100713
   PubMed Web of Science ®Google Scholar
• GouSJXuPCChenMZhaoMHEpitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitisPLoS One201384e6053023577119
   PubMed Web of Science ®Google Scholar
• TomizawaKNagaoTKusunokiRReduction of MPO-ANCA epitopes in SCG/Kj mice by 15-deoxyspergualin treatment restricted by IgG2b associated with crescentic glomerulonephritisRheumatology20104971245125620378710
   PubMed Web of Science ®Google Scholar
• KelseyRVasculitis: epitope specificity responsible for MPO-ANCA pathogenicityNat Rev Nephrol201396310
   PubMedGoogle Scholar
• OkanoTTakeuchiSSomaYPresence of anti-phosphatidylserine-prothrombin complex antibodies and anti-moesin antibodies in patients with polyarteritisnodosaJ Dermatol2017441182227345569
   PubMed Web of Science ®Google Scholar
• CarneyEFVasculitis: potential role of an anti-moesin autoantibody in MPO-AAVNat Rev Nephrol201410265
   PubMedGoogle Scholar
• Paiva-LopesMJDelgado AlvesJPsoriasis-associated vascular disease: the role of HDLJ Biomed Sci20172417328911329
   PubMed Web of Science ®Google Scholar
• HadfieldKAPattisonDIBrownBEMyeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl)Biochem J2013449253154223088652
   PubMed Web of Science ®Google Scholar
• HuangYWuZRiwantoMMyeloperoxidase, paraoxonase-1, and HDL form a functional ternary complexJ Clin Invest201312393815382823908111
   PubMed Web of Science ®Google Scholar
• HuangYDidonatoJALevisonBSAn abundant dysfunctional apolipoprotein A1 in human atheromaNat Med201420219320324464187
   PubMed Web of Science ®Google Scholar
• KamedaTOhkawaRYanoKEffects of myeloperoxidase-induced oxidation on antiatherogenic functions of high-density lipoproteinJ Lipids20152015918
   Google Scholar
• MatsuyamaASakaiNHiraokaHHiranoKYamashitaSCell surface-expressed moesin-like HDL/apoA-I binding protein promotes cholesterol efflux from human macrophagesJ Lipid Res2006471788616251720
   PubMed Web of Science ®Google Scholar
• ShaoBPennathurSHeineckeJWMyeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesionsJ Biol Chem201228796375638622219194
   PubMed Web of Science ®Google Scholar
• KamedaTUsamiYShimadaSDetermination of myeloperoxidase-induced apoAI-apoAII heterodimers in high-density lipoproteinAnn Clin Lab Sci201242438439123090734
   PubMed Web of Science ®Google Scholar